Osteopenia in β-thalassaemia major;Osteopenie bei β-Thalassaemia maior

Schweizerische Medizinische Wochenschrift

Volumn 126, Issue 44, 1996, Pages 1867-1874

  Brandle M ^a   Galeazzi, R L ^a   Morant, R ^a   Oesterle, M ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMENORRHEA; ARTICLE; BETA THALASSEMIA; BONE DENSITY; CLINICAL ARTICLE; DELAYED PUBERTY; ENDOCRINE DISEASE; FEMALE; HEMOCHROMATOSIS; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; OSTEOPENIA; SHORT STATURE; THALASSEMIA MAJOR;

ADULT; AMENORRHEA; BETA-THALASSEMIA; BLOOD TRANSFUSION; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; HEMOCHROMATOSIS; HUMANS; HYPOGONADISM; PUBERTY, DELAYED;

EID: 0029824562     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Bunn HF: Disorders of Hemoglobin. In: Harrison's principles of internal Medicine. New York: McGraw-Hill, 1994: 1741-1743.
2. Weatherall DJ: The thalassemias. In: Williams hematology. New York: McGraw-Hill, 1995: 581-615.
3. Rund D, Rachmilewitz E: Thalassemia major 1995: older patients, new therapies. Blood Rev 1995; 9: 25-32.
4. Brittenham GM, Griffith PM, Nienhuis AW, McLaren ChE, Young NS et al.: Efficacy of desferrioxamine in preventing complications of iron overload in patients with Thalassemia major. N Engl J Med 1994; 331: 567-573.
5. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP et al.: Survival in medically treated patients with homozygous β-Thalassemia. N Engl J Med 1994; 331: 574-578.
6. Modell CB and Berdoukas VA: The clinical approach to thalassemia. New York: Grune and Stratton, 1981.
7. Vullo C, De Sanctis V, Katz M, Wonke B, Hoffbrand AV et al.: Endocrine abnormalities in thalassemia. Ann New York Acad Sci 1990; 612: 293-310.
8. Allegra A, Capra M, Cuccia L, Pulejo ML, Raineri L et al.: Hypogonadism in β-thalassemic adolescents: a characteristic pituitary-gonadal impairment. The ineffectiveness of long-term iron chelation therapy. Gynecol Endocrinol 1990; 4: 181-191.
9. Prader A, Largo RH, Molinari L, Issler T: Physical growth of Swiss children. Helv Paediat Acta 1989; Suppl. 52.
10. Costin G, Kogut MD, Hyman CB, Ortega JA: Endocrine abnormalities in thalassemia major. Am J Dis Child 1979; 133: 497-502.
11. Anastasi S, Caruso V, Magnano C, Leocata A: Complicance endocrine nella thalassemia major. Ped Med Chir 1991; 13: 63-66.
12. Kletzky OA, Costin G, Marrs RP, Bernstein G, March ChM et al.: Gonadotropin insufficiency in patients with thalassemia major. J Clin Endocrinol Metab 1979; 48: 901-906.
13. Italian working group on endocrine complications in non-endocrine diseases; thalassemia and endocrinopathies: Multicenter Study of 3092 Patients. In: Ando S et al.: Endocrine disorders in thalassemia. Berlin: Springer, 1995.
14. De Sanctis V, Vullo C, Katz M, Wonke B, Tanas R et al.: Gonadal function in patients with β-thalassaemia major. J Clin Pathol 1988; 41: 133-137.
15. Pérignon F, Brauner R, Souberbielle JC, De Montalembert M, Girot R: Croissance et fonction endocrine dans la thalassémie majeure. Arch Fr Pediatr 1993; 50: 657-663.
16. Kattamis CA, Kattamis AC: Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination. Sem Hematol 1995; 32: 269-279.
17. Postel-Vinay MC, Fonoura M, De Montalembert M, Pérignon F, Brauner R et al.: Plasma growth hormone-binding protein and liver receptor in thalassemic patients. In: Ando S et al.: Endocrine disorders in thalassemia. Berlin: Springer, 1995.
18. Giardina PJ, Grady RW: Chelation therapy in β-thalassemia: the benefits and limitations of desferrioxamine. Sem Hematol 1995; 32: 304-312.
19. Gabutti V, Piga A: Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26-36.
20. Finkelstein JS, Neer RM, Biller BMK, Crawford JD, Klibanski A: Osteopenia in men with history of delayed puberty. N Engl J Med 1992; 326: 600-604.
21. Exarchou E, Poliou C, Vretou E, Pasparakis D, Madessis G et al.: Fractures and epiphyseal deformities in β-thalassemia. Clin Orthop 1984; 189: 229-233.
22. Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A et al.: Abnormal bone metabolism in thalassemia. In: Ando S et al.: Endocrine disorders in thalassemia. Berlin: Springer, 1995.
23. Diamond T, Stiel G, Posen S: Osteoporosis in haemochromatosis: Iron excess, gonadal deficiency or other factors? Ann Intern Med 1989; 110: 430-436.
24. Anapliotou MLG, Kastanias IT, Psara P, Evangelou EA, Liparaki M et al.: The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol 1995; 42: 279-287.
25. Poortakul P, Hungspringes S, Fucharoen S: Relation between erythropoiesis and bone metabolism an thalassemia. N Engl J Med 1981; 304: 1470-1473.
26. Emans JS, Grace E, Hoffer FA, Gundberg C, Ravnikar V et al.: Estrogen deficiency in adolescents and young adults: Impact on bone mineral content and effects of estrogen replacement therapy. Obstet Gynecol 1990; 76: 585-592.
27. Goni MH, Markussis V, Tolis G: Bone mineral content by single- and dual-photon absorptiometry in thalassemic patients. In: Ando S et al.: Endocrine disorders in thalassemia. Berlin: Springer, 1995.
28. Eyres KS, McCloskey EV, Fern ED, Rogers S, Beneton M et al.: Osteoporotic fractures: an unusual presentation of haemochromatosis. Bone 1992; 13: 431-433.
29. Chow LH, Frei JV, Hodsman AA, Valberg LS: Low serum 25-hydroxyvitamin D in hereditary haemochromatosis: relation to iron status. Gastroenterology 1985; 88: 865-869.
30. Dandona P, Menon RK, Houlder S: Serum 1,25 dihydroxyvitamin D and osteocalcin concentrations in thalassaemia major. Arch Dis Child 1992; 62: 474-477.
31. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH et al.: Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990; 323: 713-719.
32. De Virgilis S, Congia M, Frau F, Argiolu F, Diana G et al.: Desferrioxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988; 113: 661-669.
33. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM et al.: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332: 918-922.
34. Al-Refaie FN, Hershko C, Kosaryan M, Olivieri NF, Tondury P et al.: Results of long-term deferiprone (L1) therapy: a report by the international study group on oral iron chelators. Br J Haematol 1995; 91: 224-229.
35. Olivieri NF: Long-term therapy with deferiprone. Acta Haematol 1996; 95: 37-48.
36. Katz M, De Sanctis V, Vullo C, Wonke B, McGarrigle HHG et al.: Pharmakokinetics of sex steroids in patients with β-thalassaemia major. J Clin Pathol 1993; 46: 660-664.
37. Illig R, De Campo C and Lang-Mauritano MR: A physiological mode of puberty induction in hypogonadal girls by low dose transdermal 17 β-oestradiol. Eur J Pediatr 1990; 150: 86-91.
38. De Sanctis V, Katz M, Vullo C, Bagni B, Wonke B et al.: Effect of different treatment regimes on linear growth and final height in β-thalassaemia major. Clin Endocrinol 1994; 40: 791-798.
39. Riggs BL, Melton III LJ: The prevention and treatment of osteoporosis. N Engl J Med 1992; 327: 620-627.